Nintedanib reduces neutrophil chemotaxis via activating GRK2 in bleomycin-induced pulmonary fibrosis

30Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Neutrophils are involved in the alveolitis of idiopathic pulmonary fibrosis (IPF). However, their pathogenic mechanisms are still poorly understood. Nintedanib has antifibrotic and anti-inflammatory activity in IPF. This study aimed to investigate the regulatory mechanism of nintedanib on neutrophil chemotaxis in bleomycin (BLM)-induced pulmonary fibrosis. Nintedanib was administered via oral gavage to male C57BL/6 mice 24 h after a bleomycin intratracheal injection (1.5 U/kg). Lung histopathological findings, the expression of cytokines, and the regulatory signaling pathways of neutrophil chemotaxis were analyzed. The effect of nintedanib was also investigated in a mouse model with adoptive neutrophil transfer in vivo. Nintedanib significantly decreased the histopathological changes and neutrophil recruitment in BLM-induced pulmonary fibrosis. Nintedanib mediated a downregulation of chemokine (C-X-C motif) receptor 2 (CXCR2) and very late antigen 4 (VLA-4) expression, as well as an upregulation of G protein-coupled receptor kinase 2 (GRK2) activity in peripheral blood neutrophils in BLM-induced pulmonary fibrosis. Nintedanib also decreased the activation of endothelial cells by the decreased expression of vascular cell adhesion molecule 1 (VCAM-1). The effect of nintedanib on regulating neutrophil chemotaxis was also confirmed by a mouse model with adoptive neutrophil transfer in vivo. In conclusion, nintedanib reduces neutrophil chemotaxis and endothelial cell activation to regulate the severity of BLM-induced pulmonary fibrosis. These effects are associated with an enhancement of GRK2 activity and a reduction in CXCR2 and VLA-4 expression on neutrophils and a decrease in VCAM-1 expression on endothelial cells.

References Powered by Scopus

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management

6171Citations
N/AReaders
Get full text

The acute respiratory distress syndrome

4745Citations
N/AReaders
Get full text

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

3538Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics

24Citations
N/AReaders
Get full text

Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction

19Citations
N/AReaders
Get full text

Nintedanib solid lipid nanoparticles improve oral bioavailability and ameliorate pulmonary fibrosis in vitro and in vivo models

18Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, W. C., Chen, N. J., Chen, H. P., Yu, W. K., Su, V. Y. F., Chen, H., … Yang, K. Y. (2020). Nintedanib reduces neutrophil chemotaxis via activating GRK2 in bleomycin-induced pulmonary fibrosis. International Journal of Molecular Sciences, 21(13), 1–16. https://doi.org/10.3390/ijms21134735

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

69%

Researcher 4

31%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

45%

Biochemistry, Genetics and Molecular Bi... 3

27%

Pharmacology, Toxicology and Pharmaceut... 2

18%

Computer Science 1

9%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free